IQOS | Altria Group and Philip Morris USA

FDA Authorizes IQOS to be Marketed as Modified Risk Tobacco Product

The U.S. Food and Drug Administration (FDA) has given Altria Group the ok to market its heat not burn device, IQOS, as a modified...
FDA Advisory Panel Deals Blow to Phillip Morris International’s iQOS Device

FDA Advisory Panel Deals Blow to Phillip Morris International’s iQOS Device

Phillips Morris International, Inc. was dealt a slight blow on Thursday when a group of U.S. health advisers offered the opinion that the big...
PMI iQOS FDA Harm Reduction

Is the FDA on the Brink of True Harm Reduction?

In July, the FDA announced a new regulatory plan to focus on reducing nicotine levels in cigarettes, with the purpose of reducing cigarette addiction....
FDA Grants Modified Risk Authorization to 22nd Century Group's VLN

FDA Grants Modified Risk Authorization to 22nd Century Group’s VLN

22nd Century Group, Inc., a leading agricultural biotechnology company that is focused on tobacco harm reduction and reduced nicotine tobacco products, has announced that...
IQOS | Altria and Philip Morris Intrnational End U.S. Commercialization Agreement

Philip Morris International to Regain Full U.S. Commercial Rights to IQOS

Altria has reached an agreement with Philip Morris International (PMI) relating to the IQOS Tobacco Heating System. Altria has revealed that it will receive...
British American Tobacco Releases 2018 Harm Reduction Focus Report

British American Tobacco Releases 2018 Harm Reduction Focus Report

Harm reduction has been a major initiative and focus of British American Tobacco (BAT) in recent years and 2018 was no different. With the...
- Advertisement -